Olanzapine News and Research

RSS
Olanzapine (trade names Zyprexa, Zyprexa Zydis, Zalasta, Zolafren, Olzapin, Rexapin or in combination with fluoxetine Symbyax) is an atypical antipsychotic, approved by the FDA for the treatment of schizophrenia and bipolar disorder.
Mylan receives final FDA approval for generic Zyprexa ANDA

Mylan receives final FDA approval for generic Zyprexa ANDA

Olanzapine improves survival in mouse model of anorexia nervosa

Olanzapine improves survival in mouse model of anorexia nervosa

Weight gain or loss may also depend on medicines taken

Weight gain or loss may also depend on medicines taken

Dr. Reddy’s third quarter revenues increase 46% to $522 million

Dr. Reddy’s third quarter revenues increase 46% to $522 million

New report finds little evidence to support off-label use of atypical antipsychotics

New report finds little evidence to support off-label use of atypical antipsychotics

Benefits and harms vary among atypical antipsychotics for off-label use

Benefits and harms vary among atypical antipsychotics for off-label use

Study may help explain why antipsychotic drugs can promote overeating, weight gain

Study may help explain why antipsychotic drugs can promote overeating, weight gain

Study reports significant decline in second-generation medication use for dementia

Study reports significant decline in second-generation medication use for dementia

Unintended direct conflict between pharmaceutical marketing and public health

Unintended direct conflict between pharmaceutical marketing and public health

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

No difference in risk of nonsuicide death between ziprasidone and olanzapine for schizophrenia

No difference in risk of nonsuicide death between ziprasidone and olanzapine for schizophrenia

Court of Appeals favors Lilly in third-party payor suit

Court of Appeals favors Lilly in third-party payor suit

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

SureGene collaborates with Medco Health Solutions to conduct REST study

SureGene collaborates with Medco Health Solutions to conduct REST study

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Drug trend for children increased 10.8% in 2009 across America

Drug trend for children increased 10.8% in 2009 across America

Decrease in manic symptoms severity influences prescribing decisions for bipolar mania

Decrease in manic symptoms severity influences prescribing decisions for bipolar mania

Obecure granted patent covering betahistine with olanzapine for mitigating antipsychotic drug associated weight gain

Obecure granted patent covering betahistine with olanzapine for mitigating antipsychotic drug associated weight gain

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine